Choreo LLC Has $3.15 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Choreo LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 32.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,107 shares of the company's stock after selling 9,301 shares during the quarter. Choreo LLC's holdings in Zoetis were worth $3,146,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ZTS. Navigoe LLC purchased a new stake in Zoetis during the fourth quarter worth approximately $30,000. Cornerstone Planning Group LLC raised its position in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares in the last quarter. Murphy & Mullick Capital Management Corp purchased a new stake in shares of Zoetis in the fourth quarter worth about $44,000. Finally, Sound Income Strategies LLC grew its stake in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock traded down $0.90 during trading on Friday, hitting $151.92. 3,326,080 shares of the company's stock traded hands, compared to its average volume of 2,967,721. The stock has a market capitalization of $67.64 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 2.52 and a beta of 0.91. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock has a fifty day moving average price of $159.91 and a two-hundred day moving average price of $160.99. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their target price on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Monday, May 12th. UBS Group dropped their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $204.63.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.